The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL patients who are not eligible for autologous stem cell transplant, Roche ...

3M raised its full-year earnings outlook after beating expectations in the second quarter. American Express posted higher revenue in the second quarter, driven by a 20% jump in card fees. The company ...

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used in the proposed dosages for previously treated adult patients with ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

US and European stock markets stalled or trimmed gains on Friday after a bullish week buoyed by US data and upbeat company ...

GSK plc GSK announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

Upbeat company earnings and healthy US data buoyed stock markets on Friday, pushing ongoing concerns about President Donald ...